As of 1 February 2024, Australians with unresectable or metastatic melanoma will have a new treatment option subsidised by the Pharmaceutical Benefits Scheme (PBS) with Opdualag (nivolumab/relatlimab) becoming available to patients at a government-subsidised price.
The treatment is a combination of immunotherapies designed to help the body fight melanoma and the new listing is expected to benefit about 940 patients each year.
Read more from the Prime Minister’s press release here: https://www.pm.gov.au/media/australians-save-250-million-thanks-albanese-government-cheaper-medicines